Welcome to our dedicated page for Praxis Precision Medicines SEC filings (Ticker: PRAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Praxis Precision Medicines filings document regulatory disclosures for a CNS-focused biopharmaceutical issuer with common stock listed on the Nasdaq Global Select Market under PRAX. Its Form 8-K and 8-K/A reports cover material events, operating and financial results, clinical and regulatory updates, capital-structure disclosures, and leadership or board changes.
The company’s filing record includes disclosures related to ulixacaltamide HCl for essential tremor, elsunersen in SCN2A developmental and epileptic encephalopathy, and broader pipeline programs in movement disorders and epilepsy. Proxy materials address annual meeting matters, board composition, committee assignments, executive compensation, equity awards and other governance subjects.
Praxis Precision Medicines Chief Executive Officer Marcio Souza reported an automatic share disposition related to tax withholding. On January 7, 2026, 405 shares of common stock were withheld by the company at a price of $292.63 per share to satisfy tax obligations tied to the vesting of previously reported restricted stock units. This was not an open-market sale. After this transaction, Souza beneficially owned 53,502 common shares directly and an additional 2,600 common shares indirectly, which are held by his spouse.
Praxis Precision Medicines, Inc. (PRAX) filed an initial ownership report for Chief Operating Officer Megan Sniecinski as of January 1, 2026. She beneficially owns 20,877 shares of common stock, which include unvested restricted stock units that settle in common shares. In addition, she holds multiple stock options covering blocks of common stock at exercise prices ranging from $31.8 to $257.25, with vesting schedules spanning several years and expirations extending to 2035. All reported holdings are listed as directly owned.
Praxis Precision Medicines reported leadership changes. The company appointed Megan Sniecinski as Chief Operating Officer, effective January 1, 2026. She previously served as Chief Business Officer since 2021 and has held senior roles at BioCryst Pharmaceuticals, PTC Therapeutics and Merck. In connection with her new role, her annual base salary was set at $626,000 with a 2026 target bonus equal to 50% of base salary, and she will continue to participate in standard executive employment and indemnification arrangements.
The Board also elected Jeffrey B. Kindler and Stuart A. Arbuckle as independent Class II directors, each serving until the 2028 annual meeting of stockholders or until a successor is elected and qualified. Both will receive compensation under the company’s Non-Employee Director Compensation Policy, including an initial stock option award, annual cash retainer and annual stock option award. Each entered into the company’s standard indemnification agreement, and there are no related person transactions or special arrangements tied to their selection.
Praxis Precision Medicines, Inc. entered into an underwriting agreement for an underwritten public offering of 2,212,000 shares of its common stock at $260.00 per share. Underwriters were also granted an option to purchase up to 331,800 additional shares, which was exercised in full on January 7, 2026. Net proceeds from the offering are expected to be approximately $621.2 million after underwriting discounts, commissions and estimated expenses.
The company plans to use the cash, together with existing cash, cash equivalents and marketable securities, to prepare for potential commercialization of late-stage product candidates, continue research and development of clinical-stage and earlier-stage programs, and for working capital and general corporate purposes. Praxis believes this funding, combined with current resources, will be sufficient to cover operating expenses and capital expenditure requirements into 2028, although this depends on assumptions that may change.
Praxis Precision Medicines, Inc. is issuing 2,212,000 shares of common stock at $260.00 per share in an underwritten public offering, with underwriters holding a 30-day option to buy up to 331,800 additional shares. The deal is expected to generate approximately $540.1 million in net proceeds, which, combined with about $925 million in cash, cash equivalents and marketable securities as of December 31, 2025, is expected to fund operating needs into 2028.
The company plans to use the cash to prepare for potential commercialization of late-stage product candidates, continue clinical development, advance earlier-stage CNS programs, and for general corporate purposes. Shares outstanding will increase from 25,195,092 to 27,407,092 after the offering (excluding the option), and new investors face dilution of $222.20 per share based on an as adjusted net tangible book value of $37.80 versus the $260.00 offering price.
Praxis Precision Medicines reported preliminary year-end liquidity, stating that as of December 31, 2025 its cash, cash equivalents and marketable securities totaled approximately $925 million. This figure is based on unaudited internal information and management estimates for the year and is still subject to the company’s normal year-end closing procedures.
The company emphasized that its independent registered public accounting firm has not audited or reviewed this estimate and does not provide any assurance on it. The disclosure is being furnished rather than filed, meaning it is provided for investor information but is not automatically incorporated into other securities law filings unless specifically referenced.
Praxis Precision Medicines reported preliminary year-end liquidity, stating that as of December 31, 2025 its cash, cash equivalents and marketable securities totaled approximately $925 million. This figure is based on unaudited internal information and management estimates for the year and is still subject to the company’s normal year-end closing procedures.
The company emphasized that its independent registered public accounting firm has not audited or reviewed this estimate and does not provide any assurance on it. The disclosure is being furnished rather than filed, meaning it is provided for investor information but is not automatically incorporated into other securities law filings unless specifically referenced.
Praxis Precision Medicines, Inc. is conducting a primary offering of common stock and pre-funded warrants to raise cash for its neurology drug pipeline. The company will sell newly issued shares and, for certain investors, pre-funded warrants that are exercisable at $0.0001 per share, with ownership caps to limit any holder’s voting stake. As of December 31, 2025, Praxis reported preliminary cash, cash equivalents and marketable securities of approximately $925 million, giving it substantial funding alongside the new capital raise. The company expects to use proceeds, together with existing cash, to prepare for potential commercialization of late-stage product candidates, continue clinical development, advance earlier-stage programs and fund general corporate needs.
Praxis Precision Medicines, Inc. is conducting a primary offering of common stock and pre-funded warrants to raise cash for its neurology drug pipeline. The company will sell newly issued shares and, for certain investors, pre-funded warrants that are exercisable at $0.0001 per share, with ownership caps to limit any holder’s voting stake. As of December 31, 2025, Praxis reported preliminary cash, cash equivalents and marketable securities of approximately $925 million, giving it substantial funding alongside the new capital raise. The company expects to use proceeds, together with existing cash, to prepare for potential commercialization of late-stage product candidates, continue clinical development, advance earlier-stage programs and fund general corporate needs.
Praxis Precision Medicines reported multiple advances across its neurology pipeline. For ulixacaltamide, the company completed a successful pre-New Drug Application meeting with the U.S. Food and Drug Administration and gained alignment on NDA content, and now expects to finish its NDA submission in early 2026.
For relutrigine, Praxis announced positive registrational EMBOLD results in patients with SCN2A and SCN8A developmental and epileptic encephalopathies. Patients on relutrigine (n=51) achieved a 53% placebo-adjusted reduction in seizures over 16 weeks and a 66% increase in motor seizure-free days, with statistically significant improvements in clinician and caregiver global impression scores and no drug-related serious adverse events. Praxis plans to meet with the FDA and set NDA timing afterward.
For vormatrigine, full RADIANT data in focal onset seizures showed an 8-week 54% median seizure reduction, with FOS patients reaching 100% median weekly seizure reduction by week 8 and maintaining this through 16 weeks; more than 11% were seizure-free for the entire 8-week period and roughly one third for a consecutive 28-day period. Recruitment is complete for the POWER1 pivotal study in focal onset seizures, POWER2 is on track to finish in the second half of 2026, and the POWER3 monotherapy study is expected to begin in the first half of 2026.
Praxis Precision Medicines Chief Financial Officer reports stock purchase under employee plan
The Chief Financial Officer of Praxis Precision Medicines, Inc. (PRAX) filed a Form 4 disclosing the acquisition of company stock through the Praxis Precision Medicines, Inc. Employee Stock Purchase Plan. On 11/14/2025, the officer acquired 384 shares of common stock at a price of $31.62 per share in a transaction reported as an acquisition. Following this transaction, the officer beneficially owns 24,663 shares of Praxis common stock directly. The filing notes that the purchase was made under an employee stock purchase plan in transactions that were exempt under Rule 16b-3(d) and Rule 16b-3(c), which govern certain insider transactions for reporting and short-swing profit rules.
Praxis Precision Medicines (PRAX) insider filing: the company’s General Counsel and Secretary reported multiple stock option exercises and related share sales on 11/20/2025. The officer exercised options to acquire blocks of common stock at exercise prices of $44.4, $56.94, $83.85 and $133.65, then sold shares in several transactions, including 1,714 shares at a weighted average price of $190.863, 13,339 shares at $192.533, 977 shares at $193.233 and 9,100 shares at $194.3. After these transactions, the reporting person directly owned 20,831.667 shares of Praxis common stock, along with remaining stock options over additional shares that vest over time. The filing notes that the transactions were effected for estate planning purposes.